VivoSeq
Immunology

Allergic Bronchopulmonary Aspergillosis

10

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Allergic Bronchopulmonary Aspergillosis is an early-stage landscape with 10 programs across 9 companies. The most active players are Prism Pharmaceuticals, Gilead, Sebela Pharmaceuticals Development LLC. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2S

Sebela Pharmaceuticals Development LLC

1 program

Phase 3Amgen logo

Amgen

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed8 · 89%
Recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT06174922·300 enrolled
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT00974766·92 enrolled
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT01321827·100 enrolled
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT01857479·21 enrolled
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
Completed·PPoitiers University Hospital·Phase 2·NCT02273661·174 enrolled
A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT03133299·30 enrolled
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT02440009·191 enrolled
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT01621321·50 enrolled
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Completed·Regeneron logoRegeneron·Phase 2·NCT04442269·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)